AUROBAC

Serial Number 79375815
Registration 7525724
700

Registration Progress

Application Filed
Jun 15, 2023
Under Examination
Approved for Publication
Jul 23, 2024
Published for Opposition
Jul 23, 2024
Registered
Oct 8, 2024

Basic Information

Serial Number
79375815
Registration Number
7525724
Filing Date
June 15, 2023
Registration Date
October 8, 2024
Published for Opposition
July 23, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 8, 2024
Registration
Registered
Classes
005 042

Rights Holder

AUROBAC THERAPEUTICS SAS

34
Address
29 avenue Tony Garnier
F-69007 LYON
FR

Ownership History

AUROBAC THERAPEUTICS SAS

Original Applicant
34
FR

AUROBAC THERAPEUTICS SAS

Owner at Publication
34
FR

AUROBAC THERAPEUTICS SAS

Original Registrant
34
FR

Legal Representation

Attorney
Mitchell Radin

USPTO Deadlines

Next Deadline
1917 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-10-08)
Due Date
October 08, 2030
Grace Period Ends
April 08, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description
Apr 4, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 19, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB
Mar 19, 2025 FIMP P FINAL DISPOSITION PROCESSED
Jan 17, 2025 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 8, 2025 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 1, 2025 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 1, 2025 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 8, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 8, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Jul 23, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2024 PUBO A PUBLISHED FOR OPPOSITION
Jul 3, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 14, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jun 14, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED
Jun 14, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 14, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED
Jun 14, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 7, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 7, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 23, 2024 RFNT P REFUSAL PROCESSED BY IB
Mar 30, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 29, 2024 RFRR P REFUSAL PROCESSED BY MPU
Mar 12, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 11, 2024 CNRT R NON-FINAL ACTION WRITTEN
Mar 5, 2024 DOCK D ASSIGNED TO EXAMINER
Aug 11, 2023 MAFR O APPLICATION FILING RECEIPT MAILED
Aug 7, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 4, 2023 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB

Detailed Classifications

Class 005
Pharmaceutical and veterinary products, namely pharmaceutical and veterinary preparations for prevention and treatment of infectious diseases and critical care conditions, namely, systemic inflammatory response syndrome (SIRS), sepsis, and septic shock, as well as related diseases and co-morbidities; dietetic food and dietetic substances being preparations for medical or veterinary use
Class 042
Scientific and technological services, namely, pharmaceutical drug development services as well as research and design services relating thereto; industrial analysis and research services, namely, research and development of new products for third parties; medical research services; research services in the fields of biology, bacteriology, and chemistry; clinical research in the field of infectious diseases and critical care; Scientific research in the nature of conducting clinical trials for others; development of pharmaceutical products

Classification

International Classes
005 042